Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials.

[1]  P. Rothwell,et al.  Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials , 2012, The Lancet.

[2]  Gianni Tognoni,et al.  Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials , 2012, The Lancet.

[3]  N. Sattar,et al.  Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. , 2012, Archives of internal medicine.

[4]  Rodney J Scott,et al.  Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial , 2011, The Lancet.

[5]  P. Rothwell,et al.  Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview , 2011, Cancer Prevention Research.

[6]  Peter M. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomized trials , 2011 .

[7]  P. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials , 2011, The Lancet.

[8]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[9]  A. Jemal,et al.  Global Patterns of Cancer Incidence and Mortality Rates and Trends , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[10]  S. Ogino,et al.  Aspirin use and survival after diagnosis of colorectal cancer. , 2009, JAMA.

[11]  M. Thun,et al.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. , 2009, The Lancet. Oncology.

[12]  P. Elwood,et al.  Aspirin, salicylates, and cancer , 2009, The Lancet.

[13]  J. Baron,et al.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. , 2009, Journal of the National Cancer Institute.

[14]  F. Murray,et al.  Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age? , 2009, Expert opinion on therapeutic targets.

[15]  W. Hung.  Anti‐metastatic Action of Non‐steroidal Anti‐inflammatory Drugs , 2008, The Kaohsiung journal of medical sciences.

[16]  L. Kopelovich,et al.  Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. , 2007, Cancer research.

[17]  P. Rothwell,et al.  Commentary: aspirin and colorectal cancer an epidemiological success story. , 2007, International journal of epidemiology.

[18]  J. Hippisley-Cox,et al.  Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. , 2007, Gastroenterology.

[19]  P. Rothwell,et al.  Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies , 2007, The Lancet.

[20]  M. Thun,et al.  A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. , 2007, Journal of the National Cancer Institute.

[21]  L. Habel,et al.  NSAIDs and breast cancer recurrence in a prospective cohort study , 2007, Cancer Causes & Control.

[22]  B. Yawn,et al.  Routine Aspirin or Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2007, Annals of Internal Medicine.

[23]  K. Moysich,et al.  Regular Use of Aspirin and Prostate Cancer Risk (United States) , 2006, Cancer Causes & Control.

[24]  R. Millikan,et al.  Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. , 2005, American journal of epidemiology.

[25]  M. Błaszczyńska,et al.  PROSTAGLANDINS AND CANCER , 2005, Gut.

[26]  J. Manson,et al.  Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. , 2005, JAMA.

[27]  B. Graubard,et al.  Aspirin use and mortality from cancer in a prospective cohort study. , 2004, Anticancer research.

[28]  D. Lawlor,et al.  Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? , 2004, The Lancet.

[29]  W. Willett,et al.  Aspirin use in relation to risk of prostate cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[30]  James W. Vaupel,et al.  Broken Limits to Life Expectancy , 2002, Science.

[31]  K. McPherson,et al.  H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study. , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[32]  K. McPherson,et al.  An age, period and cohort analysis of pleural cancer mortality in Europe. , 2000 .

[33]  J. Rüschoff,et al.  Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Shapiro,et al.  Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma , 1998, Cancer.

[35]  T. Meade,et al.  Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk , 1998, The Lancet.

[36]  M. Thun,et al.  Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.

[37]  C Warlow,et al.  The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[38]  R. Doll,et al.  Randomised trial of prophylactic daily aspirin in British male doctors , 1988, British medical journal.

[39]  T. Gasic,et al.  Anti-metastatic effect of aspirin. , 1972, Lancet.

[40]  C. Stewart,et al.  Antimetastatic effects associated with platelet reduction. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. la Vecchia,et al.  Aspirin and cancer risk: a summary review to 2007. , 2009, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[42]  J. Meyerhardt,et al.  Aspirin dose and duration of use and risk of colorectal cancer in men. , 2008, Gastroenterology.

[43]  P. Loehrer.  Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer , 2007 .

[44]  A. Folsom,et al.  NSAID use and survival after breast cancer diagnosis in post-menopausal women , 2006, Breast Cancer Research and Treatment.

[45]  Stephen D. Persell,et al.  Low-Dose Aspirin Does Not Reduce Cancer Incidence in Women Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55. , 2005 .

[46]  J A Hanley,et al.  Nested caseÐcontrol study of the effects of non- steroidal anti-inflammatory drugs on breast cancer risk and stage , 2000 .